Palbociclib
CAS No. 571190-30-2
Palbociclib ( PD0332991;PD-0332991;PD 0332991 )
Catalog No. M15082 CAS No. 571190-30-2
A potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 43 | In Stock |
|
10MG | 61 | In Stock |
|
50MG | 80 | In Stock |
|
100MG | 87 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePalbociclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.
-
DescriptionA potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM; shows antiproliferative effect against retinoblastoma (Rb)-positive tumor cells in vitro and reduces the phospho-Ser780/Ser795 on the Rb protein; orally bioavailable.Breast Cancer Approved
-
SynonymsPD0332991;PD-0332991;PD 0332991
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK4;CDK6
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number571190-30-2
-
Formula Weight447.53
-
Molecular FormulaC24H29N7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 0.2 mg/mL (Need ultrasonic or warming)
-
SMILESCC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
-
Chemical NamePyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Toogood PL, et al. J Med Chem. 2005 Apr 7;48(7):2388-406.
2. Fry DW, et al. Mol Cancer Ther. 2004 Nov;3(11):1427-38.
3. Baughn LB, et al. Cancer Res. 2006 Aug 1;66(15):7661-7.
2. Fry DW, et al. Mol Cancer Ther. 2004 Nov;3(11):1427-38.
3. Baughn LB, et al. Cancer Res. 2006 Aug 1;66(15):7661-7.
molnova catalog
related products
-
Senexin-A
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
CYC065
CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.
-
FN-1501
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).